Status:
COMPLETED
Salbutamol, Pharmacogenetics and Breathing Mechanics
Lead Sponsor:
University of British Columbia
Collaborating Sponsors:
World Anti-Doping Agency
Conditions:
Bronchoconstriction
Inhaled Salbutamol
Eligibility:
All Genders
19-45 years
Phase:
PHASE4
Brief Summary
Athletes using asthma medications called β2-agonists win a disproportionately high number of medals at Olympic Games. Due to a large variety in the genes that affect how individuals respond to β2-agon...
Eligibility Criteria
Inclusion
- trained, experienced cyclists
- maximal oxygen consumption of at least 50ml/kg/min or 4l/min for women; and 60ml/kg/min or 5l/min for men
- athletes with and without exercise-induced bronchoconstriction
Exclusion
- any uncontrolled heart or lung condition
- maximal oxygen consumption of less than 50ml/kg/min or 4L/min for women; and less than 60ml/kg/min or 5L/min for men
- pregnancy
- smoking
Key Trial Info
Start Date :
May 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2016
Estimated Enrollment :
94 Patients enrolled
Trial Details
Trial ID
NCT01903785
Start Date
May 1 2013
End Date
August 1 2016
Last Update
November 2 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Environmental Physiology Laboratory, University of British Columbia
Vancouver, British Columbia, Canada, V6T 1Z1